Jonathan E Rosenberg

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

N. Socci, B. Taylor, N. Schultz, 2014, Cancer discovery.

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

P. Ascierto, B. Mellado, P. Sharma, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma

G. Iyer, H. Al-Ahmadie, M. Callahan, 2023, The Journal of pathology.